Bionano Genomics
BNGO | NASDAQ
$0.94
-$0.06 (-6.00%)
At close: Nov 16, 2026, 4:00 PM ET
$0.99
+$0.05 (+5.32%)
After-hours:
Nov 16, 2026, 7:51 PM ET
Bionano Genomics Company Profile
Company profile explainedCompany Profile
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles. The Saphyr platform includes the Saphyr instrument, a device capable of imaging single molecules; the Saphyr Chip, a disposable component equipped with nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide essential reagents and protocols for extracting and tagging ultra-high molecular weight DNA. Furthermore, Bionano Genomics supplies Saphyr and Bionano compute servers to support its analytical operations. It also offers NxClinical, a single software system designed for the analysis and interpretation of genomic variants identified through microarray and next-generation sequencing data, serving both cytogenetics and molecular genetics applications. In addition to its product line, Bionano Genomics delivers a variety of specialized testing and laboratory services. These include: FirstStepDx PLUS: A chromosomal microarray service used to identify underlying genetic causes in individuals with autism spectrum disorder, developmental delay, and intellectual disability. Fragile X syndrome (FXS) testing services: Comprehensive diagnostic testing for FXS. NextStepDx PLUS: An exome sequencing test aimed at detecting genetic variants associated with childhood developmental disorders. EpiPanelDx PLUS: A genetic testing panel for patients experiencing seizures, infantile spasms, encephalopathy, or febrile seizures. PGx test: A pharmacogenomics test that identifies over 60 alleles across 11 genes relevant to drug response. Bionano Genomics was founded in 2003 and operates from its corporate headquarters in San Diego, California.
Key Executives
| Name | Position |
|---|---|
| Albert A. Luderer | Chairman, Interim CEO, Interim President & Interim Principal Financial Officer |
| Cory Kreeck | Chief People Officer |
| Jonathan Dixon | Chief Legal Officer & Corporate Secretary |
| Mark Oldakowski | Chief Operating Officer |
| Alex Hastie | Chief Scientific Officer |
| Mark Adamchak | Chief Accounting Officer, Principal Accounting Officer & Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | S-1 | Filing |
| Oct 19, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 14, 2026 | 8-K | Current Report |
| Sep 09, 2026 | 4 | Filing |
| Aug 21, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 10, 2026 | 10-Q | Quarterly Report |
| Aug 10, 2026 | 8-K | Current Report |
| Aug 05, 2026 | 4 | Filing |
| Aug 05, 2026 | 4 | Filing |
Bionano Genomics
| Country | United States |
| IPO Date | Aug 21, 2018 |
| Industry | Medical - Instruments & Supplies |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Albert A. Luderer |
Contact Details
9540 Towne Centre Drive San Diego,
California 92121 United States
Stock Details
| Ticker Symbol | BNGO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001411690 |
| CUSIP Number | 09075F404 |
| ISIN Number | US09075F4046 |
| SIC Code | 3826 |
Add to Watchlist
Select watchlists to add or remove BNGO